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Abstract
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting both joints and extra-articular tissues.
Although some genetic risk factors for RA are well-established, most notably HLA-DRB1 and PTPN22, these markers do not
fully account for the observed heritability. To identify additional susceptibility loci, we carried out a multi-tiered, case-
control association study, genotyping 25,966 putative functional SNPs in 475 white North American RA patients and 475
matched controls. Significant markers were genotyped in two additional, independent, white case-control sample sets (661
cases/1322 controls from North America and 596 cases/705 controls from The Netherlands) identifying a SNP, rs1953126, on
chromosome 9q33.2 that was significantly associated with RA (ORcommon = 1.28, trend Pcomb = 1.45E-06). Through a
comprehensive fine-scale-mapping SNP-selection procedure, 137 additional SNPs in a 668 kb region from MEGF9 to STOM
on 9q33.2 were chosen for follow-up genotyping in a staged-approach. Significant single marker results (Pcomb,0.01)
spanned a large 525 kb region from FBXW2 to GSN. However, a variety of analyses identified SNPs in a 70 kb region
extending from the third intron of PHF19 across TRAF1 into the TRAF1-C5 intergenic region, but excluding the C5 coding
region, as the most interesting (trend Pcomb: 1.45E-06 R 5.41E-09). The observed association patterns for these SNPs had
heightened statistical significance and a higher degree of consistency across sample sets. In addition, the allele frequencies
for these SNPs displayed reduced variability between control groups when compared to other SNPs. Lastly, in combination
with the other two known genetic risk factors, HLA-DRB1 and PTPN22, the variants reported here generate more than a 45-
fold RA-risk differential.
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Introduction
Rheumatoid arthritis is the most common systemic autoimmune
disease affecting approximately 1% of the adult population
worldwide, with prevalence varying from 0.2–0.3% in East Asians
to 6% in Pima and Chippewa Indians [1]. The disease is
characterized by inflammation of the synovial tissue and local
articular damage [2]. Disability in this inflammatory polyarthritis
primarily stems from progressive bone erosion and comorbidity
with coronary artery disease, infection and lymphoma [3,4]. As
with many other autoimmune conditions, RA affects women more
commonly than men.
Although the etiology of RA is presently unknown, studies of
RA heritability in two Northern European regions have
demonstrated that an average of 60% of the disease variance
can be attributed to genetic factors [5]. Through a combination of
linkage and association studies, alleles segregating at the human
leukocyte antigen (HLA) class II DRB1 gene on chr 6p have
consistently been shown to have strong RA-predisposing effects
[6,7]. That said, studies suggest that HLA-DRB1 accounts for at
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most 50% of the phenotypic variance due to genetic effects [8];
therefore, loci not linked to the HLA region may play a crucial
role in RA susceptibility.
Utilizing a variety of approaches such as positional mapping,
candidate gene experiments and large-scale functional genetic
association studies, several recent reports have yielded evidence for
additional RA genes. The most robust, non-MHC, RA-associated
marker is the R620W missense polymorphism in the PTPN22 gene
on chromosome 1p13, which has been repeatedly associated with RA
in individuals of European ancestry [9–11]. In addition, positional
cloning work has suggested the peptidyl arginine deiminase gene
cluster (including PADI4) underneath a linkage peak on chr 1p36 may
harbor susceptibility variants [12,13] while well-powered association
studies identified RA-associated SNPs in STAT4 [14] and the
TNFAIP3 region [15,16]. A promoter polymorphism of the Fc
receptor-like 3 gene, FCRL3, and a SNP within the RUNX1 binding
site of SLC22A4 have also been implicated in RA susceptibility [17–
19], both with conflicting reports [20,21].
Interestingly, some of these disease-associated polymorphisms
appear to have heterogeneity in effect sizes across ethnic groups;
for example, the disease-associated variants in PADI4 and FCRL3
have a strong effect in East Asians but little effect in whites of
European descent [10,22]. Similarly, the PTPN22 W620 risk allele
is virtually absent in East Asians and therefore plays no role in RA
risk in these populations [11]. As RA is a major cause of disability
and is correlated with increased mortality in severe cases, genetic
studies promise to improve public health. Importantly, as
predicted by careful meta-analyses of linkage studies [23], some
RA-susceptibility variants show pleiotropic effects across many
autoimmune diseases [e.g. 11,14,24,25]. Consequently, further
identification of RA genetic risk factors should aid in elucidating
the underlying mechanisms of autoimmunity, in general, and may
substantially impact drug discovery through the development of
targeted diagnostics and therapeutics.
Arguing that the power of linkage disequilibrium-based designs
to map disease alleles is high compared to other approaches, Jorde
[26], Risch and Merikangas [27] and Long and colleagues [28]
helped motivate the recent wave of successful genome-wide disease
association studies. Propelled by technological developments, this
shift has recently transformed common, complex disease gene
mapping resulting in a number of convincing susceptibility
variants [e.g. 29–31]. We took a large-scale candidate SNP
association approach, very similar to that used in our recent study
of psoriasis [32], to interrogate the genome for genetic variants
that predispose individuals to RA. This genome-wide SNP panel
(25,966 SNPs), which is primarily composed of missense (70%),
acceptor/donor splice site and putative transcription-factor
binding site SNPs, was applied to a multi-tiered, case-control
association study of RA that incorporated replication of associa-
tion effects as a key feature of the study design. By directly
interrogating polymorphisms with higher likelihoods of producing
biologically disruptive effects across multiple large sample sets, our
aim was to maximize power to detect RA susceptibility genes.
We previously reported the identity of the RA-associated
PTPN22 R620W variant which was discovered in the first step
(quality control of all DNA samples) of our RA scan [9,33]. Here,
we report our finding of variants in the PHF19-TRAF1-C5 region
on chromosome 9q33.2 that show strong and consistent
association across three independent RA case-control studies
(1732 cases/2502 controls), paralleling and extending the results of
a whole-genome association study [34] and a candidate gene study
[35]. Combining genetic information from HLA, PTPN22 and
TRAF1 variants, we calculate the posterior probability of RA for
every possible genotype combination. Results such as these may
form the foundation for individualized prognosis and targeted
medicine.
Results
Identification of the RA-Associated Chr 9q33.2 Region
We are conducting three sequential case-control studies to
identify SNPs associated with RA. In the first study, DNA samples
from white North Americans with (N= 475 cases) and without
(N= 475 controls) RA (sample set 1, see Table 1 for a breakdown
of the clinical characteristics of each sample set) were genotyped
for a set of 25,966 gene-centric SNPs utilizing disease-phenotype-
based pooled DNA samples (pooled DNA samples were used to
economically increase genotyping throughput while minimizing
DNA consumption). The allele frequency of each SNP was
determined in cases and controls as described in the Methods and
1438 SNPs were significantly associated with RA using an allelic
test (P,0.05); 88 of these SNPs mapped to chr 6p21 between
HLA-F and HLA-DPB1 within the major histocompatibility
complex (MHC). Of the 1350 non-MHC SNPs, 1306 were
evaluated in a second independent white North American sample
set (661 cases and 1322 controls) by use of a similar pooling
strategy (44 SNPs were not genotyped due to insufficient primer
quantities). Eighty-nine statistically compelling SNPs (Pallelic,0.05)
with the same risk allele in these two sample sets were then
individually genotyped in sample set 1 to verify the results from the
pooled DNA phase of the experiment; 55 SNPs retained statistical
significance (Pallelic,0.05) and 44 have been individually geno-
typed in sample set 2. Twenty-eight of these were significant
(Pallelic,0.05) and are currently being evaluated in a third
independent white Dutch sample set (596 cases and 705 controls).
The most significant non-MHC SNP to emerge from a
combined analysis of sample sets 1 and 2 after the PTPN22
missense SNP, rs2476601 [9], was rs1953126 an intergenic SNP
located 1 kb upstream of the human homologue to the Drosophila
polycomblike protein-encoding gene, PHF19, on chr 9q33.2 near
Author Summary
Rheumatoid arthritis (RA), a chronic autoimmune disorder
affecting ,1% of the population, is characterized by
immune-cell–mediated destruction of the joint architec-
ture. Gene–environment interactions are thought to
underlie RA etiology. Variants within HLA-DRB1 and the
hematopoietic-specific phosphatase, PTPN22, are well
established RA-susceptibility loci, and although other
markers have been identified, they do not fully account
for the disease heritability. To identify additional suscep-
tibility alleles, we carried out a multi-tiered, case-control
association study genotyping .25,000 putative functional
SNPs; here we report our finding of RA-associated variants
in chromosome 9q33.2. A detailed genetic analysis of this
region, incorporating HapMap information, localizes the
RA-susceptibility effects to a 70 kb region that includes a
portion of PHF19, all of TRAF1, and the majority of the
TRAF1-C5 intergenic region, but excludes the C5 coding
region. In addition to providing new insights into
underlying mechanism(s) of disease and suggesting novel
therapeutic targets, these data provide the underpinnings
of a genetic signature that may predict individuals at
increased risk for developing RA. Indeed, initial analyses of
three known genetic risk factors, HLA, PTPN22, and the
chromosome 9q33.2 variants described here, suggest a
.45-fold difference in RA risk depending on an individual’s
three-locus genotype.
TRAF1 Variants on Chr 9q33.2 and RA
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two excellent candidate genes, TRAF1 and C5 (individual
genotyping: Sample Set 1: OR=1.30, 95% CI 1.08–1.58, trend
P=0.007; Sample Set 2: OR=1.35, 95% CI 1.18–1.56, trend
P=1.69E-05). This SNP was genotyped in sample set 3 showing a
nonsignificant trend towards association: OR=1.16, 95% CI
0.99–1.36, trend P= 0.066 (Table S1). No significant deviations
from Hardy-Weinberg equilibrium were observed for the
genotypes of this SNP in the cases or controls in the three sample
sets. The frequency of the minor allele was approximately 30.8%
in white North American controls increasing to 37.3% in white
North American cases and 34.9% in Dutch controls increasing to
38.3% in Dutch cases. A combined analysis across all three sample
sets was highly significant (OR=1.28, 95% CI 1.16–1.40, trend
Pcomb = 1.45E-06).
Chr 9q33.2 Fine-Mapping and LD Analyses
To further explore the association signal in this region, we used
patterns of LD from the CEU HapMap data (www.hapmap.org)
[36] to define a broad 668 kb region, extending from MEGF9 to
STOM on chr 9q33.2, for follow-up individual genotyping.
Postulating two different disease models, one where the originally
identified SNP, rs1953126, is in LD with one or more causative
SNPs and a second model of allelic heterogeneity where several
alleles at a locus independently predispose individuals to disease,
we selected a combination of 137 LD and tagging SNPs from this
region for follow-up genotyping in Sample Set 1 (Figure 1) (A
detailed description of SNP selection is outlined in the Methods).
Only four SNPs, all in the RAB14-GSN-STOM region, were mildly
out of Hardy-Weinberg equilibrium (1024,P,0.01) in the
controls (Table S1). Including the original SNP, rs1953126, 38
of the 138 chr 9q33.2-region SNPs genotyped in Sample Set 1
were significant at the 0.01 level.
To better understand these positive signals and select a subset of
informative SNPs for genotyping in our other sample sets, we next
investigated the LD architecture around rs1953126 by calculating
pairwise r2 values for all 138 SNPs genotyped in Sample Set 1.
Evaluating cases and controls separately revealed very similar LD
patterns across this region (Figure 2A). There were two primary
haplotype blocks (LD Block 1 and LD Block 2) (here an LD block
is defined as a region in which over 75% of all pairwise r2 LD
correlation values exceeded 0.3), with moderate LD between pairs
of SNPs residing within each of the two blocks. LD Block 1, which
contains the original SNP, rs1953126, and is approximately 70 kb,
extends from rs10985070, an intronic SNP in the 59 end of
PHF19, across TRAF1 into the TRAF1-C5 intergenic region to
rs2900180. Approximately 214 kb in length, LD Block 2 ranges
from the middle of C5 to the RAB14-GSN intergenic region. Given
that haplotype block structures can have complex LD patterns
within and between blocks and that we were focused on a single
associated SNP in this region (rs1953126), we present a higher
resolution plot shown in Figure 2B where pairwise r2 values were
calculated for rs1953126 and each of the remaining 137 SNPs,
revealing groups of highly correlated SNPs not readily visible in
the LD heat-map.
Integrating the Sample Set 1 association results with the LD
measures, we found that the original SNP, rs1953126, was highly
correlated (r2.0.95) with 17 other SNPs (Group 1 in
Figures 2Band 2C in LD Block 1. As predicted, these 18 SNPs
have similar association results increasing in frequency from
approximately 30–31% in controls to 36–37% in cases
(OR=1.29–1.35, trend P,0.002–0.009) (Table S1). Of interest
was the observation that 20 non-Group 1 SNPs were associated
with disease at equal or greater significance including 14 other
SNPs from LD Block 1. Thirteen of these other LD Block 1 SNPs,
which were highly correlated with one another (r2.0.95) (Group 2
in Figures 2Band 2C and reasonably correlated with the Group 1
SNPs (r2 = 0.66–0.72), had minor allele frequencies of approxi-
mately 38% in controls increasing to 46% in cases (OR=1.34–
1.39, trend P#0.002). The fourteenth significant SNP in LD Block
1, rs7021880, a TRAF1 intronic SNP, was also highly significant
(OR=1.43, trend P=3.12E-04) increasing in frequency from
27.1% in controls to 34.7% in cases. This SNP was in LD with
both Group 1 (r2 = 0.82–0.90) and Group 2 (r2 = 0.59–0.64) SNPs
(Figure 2B). The six other SNPs with P values ,0.01 lie upstream
of LD Block 1 (n= 4) or downstream of LD Block 2 in GSN (n = 2)
(Figure 1, Table S1) and, with the exception of the PSMD5
intronic SNP rs10760117, were not as significant as many of the
LD Block 1 SNPs.
Given the association results and the LD structure, we selected
72 of the 137 fine-scale mapping SNPs to genotype in Sample Set
2 (661 white North American RA patients and 1322 matched
white North American controls) (Table S1). This subset of fine-
Table 1. Demographic and clinical information.
Sample Set
Subphenotype 1a 2b 3c
Genetic background White (North American) White (North American) White (Dutch)
No. of cases 475 661 596
No. of controls 475 1322 705
Female:male 314:161 536:125 362:196d
Average age of onset (years) 46.97611.83 38.61613.61 54.58613.38e
% RF-positive 100% 82% 72%f
a138 SNPs, including rs1953126, were genotyped in this sample set. Note, all 950 samples were genotyped for a single SNP, rs10818488, in the candidate gene study
performed by Kurreeman et al [35].
b73 SNPs, including rs1953126, were genotyped in this sample set. Note, 475 of these patient samples were included in the initial whole genome association study
performed by Plenge et al [34].
c43 SNPs, including rs1953126, were genotyped in this sample set. Note, 436 patients and 94 controls samples were included in the candidate gene study performed by
Kurreeman et al [35].
dInformation on gender was available for 558 patients.
eInformation on age of onset was available for 306 patients.
fInformation on RF status was available for 440 patients.
doi:10.1371/journal.pgen.1000107.t001
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scale mapping SNPs was chosen to reduce the genotyping load,
while capturing the association signals and retaining full coverage
of the genetic variation in this region. Two of these 72 SNPs,
rs12683062 (in CEP110) in the cases and rs9409230 (a RAB14-GSN
intergenic SNP) in the controls, were moderately out of Hardy-
Weinberg equilibrium (P= 2.56E-04 and P= 0.003, respectively;
Table S1). Including the original SNP, rs1953126, 23 of these 72
SNPs were significant (trend P,0.01) in Sample Set 2; however,
the nine significant LD Block 1 SNPs in Sample Set 1 were the
most significant, replicated SNPs in Sample Set 2 (Figure 1).
Interestingly there were three SNPs in GSN (rs10985196,
rs7046030 and rs12683459), all highly correlated with pairwise
r2 values .0.90, which were highly significant (trend P,1026) in
Sample Set 2 but only marginally significant in Sample Set 1
(trend P= 0.01–0.05). The difference between the two sample sets
appears to be the result of disparate control allele frequencies – the
case allele frequencies are nearly identical between the two sample
sets (,22%) but the control allele frequencies differ by 3% (18–
19% in Sample Set 1 vs 15.5–16.5% in Sample Set 2) (Table S1).
Forty-two SNPs were genotyped in Sample Set 3 (596 white
Dutch RA patients and 705 white Dutch controls); none of these
SNPs rejected HWE at the P,0.01 significance level (Table S1).
These 42 SNPs span over 600 kb and were selected to cover
genetic variability, association patterns and gene boundaries. Four
of the 42 SNPs, spanning 286 kb from TRAF1 to RAB14, were
significant at the 0.01 level (Figure 1). Of these four, two SNPs
(rs4836834 and rs7021049) were members of Group 2 from LD
Block 1, perfectly correlated (r2 = 1) and both SNPs were highly
significant in all three sample sets. The other two significant SNPs,
rs1323472 and rs942152, were only moderately if at all significant
in Sample Sets 1 and 2. The six Group 1 SNPs genotyped in
Sample Set 3 were close to the 0.05 significance level, with the
most significant of these being the synonymous P340P TRAF1
SNP, rs2239657 and the TRAF1-C5 intergenic SNP, rs2900180
(trend P=0.052) (Table S1). The TRAF1 intronic SNP,
rs7021880, was not significant in this sample set (trend P=0.102).
In a combined analysis of the 43 SNPs genotyped in all three
sample sets, including the original SNP, rs1953126, 25 SNPs,
Figure 1. Case-control association results and linkage disequilibrium structure of the 9q33.2 region. A physical map of the 668 kb
surrounding the original associated SNP, rs1953126, with the location of all 138 markers genotyped in sample set 1 noted. The markers in red indicate
the 43 SNPs genotyped in all three sample sets. The locations of LD Block 1 and LD Block 2 are indicated. Above the physical map, the trend P-values
are displayed for the SNPs genotyped in each of the three sample sets. The red line indicates trend P= 0.01. The LD structure across the 668 kb region
from MEGF9 to STOM, based on pairwise D’ values from the CEU HapMap, is displayed below the physical map.
doi:10.1371/journal.pgen.1000107.g001
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spanning a region of over 525 kb from rs7026635 within FBXW2
to rs10818527 within GSN, were significantly associated with RA
(trend Pcomb,0.01) (Table 2). Several of these SNPs exhibited
consistent and strong association across all three sample sets (Table
S1). Using either a combined trend or genotypic P-value, the top-
ranked five SNPs were: rs6478486, rs4836834, rs2239657,
rs7021880 and rs7021049 (listed in order of position). All reside
within or near TRAF1 in LD Block 1, had common odds ratios of
approximately 1.3 and were highly significant (trend Pcomb,1.5E-
07) (Table 2).
Multiple Testing
Since false-positive results can be problematic in any large-scale
experiment in which modest nominal significance levels are used,
we corrected the results from the combined analysis for multiple
testing using the method of Dunn-Sidak [37]. Seven SNPS, all
within LD Block 1, survived a Dunn-Sidak correction for 25,966
SNPs at P,0.01. The corrected trend Pcomb values for the five
most significant SNPs were: 0.004 for rs6478486 and rs223957
(Group 1), 0.002 for rs4836834 and 0.001 for rs7021049 (Group
2), and 1.3E-04 for rs7021880.
Haplotype Sliding Window
Given that our fine-scale-mapping SNPs cluster into various
groups based on their pairwise r2 values and that under many
models haplotypes can be more informative than single-markers
[38], we used the Haplo-Stats package [39] to run a 5-SNP sliding-
window haplotype association analysis on the 43 SNPs genotyped
in all three sample sets separately for each sample set and then
combined the statistical evidence across all three sample sets. The
combined analysis revealed a 29 kb-wide maximum peak of global
association for haplotypes comprised of alleles segregating at
rs6478486-rs4836834-rs2239657-rs7021880-rs7021049 in LD
Block 1 (Pcomb= 4.15E-08) (Figure 3). This region ranges from 9
kb downstream of TRAF1 in the PHF19-TRAF1 intergenic region
to intron 3 within TRAF1. Aside from this peak and a second
highly significant peak in the TRAF1 region (Pcomb= 5.45E-08;
rs2239657-rs7021880-rs7021049-rs2900180-rs2269066), a second
region of interest was centered over the RAB14-GSN region
(P= 2.11E-06).
Of these two regions, we view the disease association evidence
to be stronger for the PHF19-TRAF1 region for several reasons:
First, combined analyses across all studies yielded the most
Figure 2. The LD architecture of the 9q33.2 region. (A) Pairwise linkage disequilibrium values (r2) for all 138 SNPs genotyped in Sample Set 1.
Cases and controls are shown separately. (B) Pairwise LD values between rs1953126 and each of the 137 other SNPs genotyped in Sample Set 1.
Locations of the two main LD blocks are shown in bold. (C) SNPs within each of the two LD groups in Block 1. SNPs in black were genotyped in this
study and are listed according to their position. SNPs in grey were not genotyped but highly correlated (r2.0.93) with either Group 1 or Group 2 SNPs
in the CEU HapMap data. Note that all of the SNPs in grey lie in LD Block 1 between rs10985070 and rs2900180.
doi:10.1371/journal.pgen.1000107.g002
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Table 2. Combined analysis of 43 chr 9q33.2 SNPs genotyped in all three RA sample sets.
Combined Analysis
Marker Gene Type Position & Allelesa ORcommon (95% CI)
b Trend Pcomb
c Genotypic Pcomb
c
rs10760112 MEGF9 intronic C122507391T 1.17 (1.02–1.23) 0.035 0.136
rs7026635 FBXW2 intronic G122589848A 1.24 (1.10–1.35) 0.001 0.012
rs10760117 PSMD5 intronic T122626558G 1.26 (1.10–1.31) 2.79E-04 0.003
rs10739575 G122645922A 1.16 (1.03–1.30) 0.081 0.349
rs933003 A122647650G 1.12 (0.79–1.40) 0.255 0.243
rs1837 PHF19 39UTR T122658050C 1.28 (1.12–1.36) 2.17E-04 0.002
rs1056567 PHF19 S181S T122671866C 1.25 (1.12–1.35) 1.11E-04 0.002
rs1953126 T122680321C 1.28 (1.16–1.40) 1.45E-06 4.24E-05
rs1609810 G122682172A 1.29 (1.19–1.42) 1.92E-07 5.24E-06
rs881375 T122692719C 1.27 (1.17–1.41) 4.69E-07 1.09E-05
rs6478486 T122695150C 1.29 (1.19–1.42) 1.35E-07 3.75E-06
rs4836834 TRAF1 39UTR T122705722A 1.32 (1.19–1.43) 8.13E-08 1.84E-06
rs2239657 TRAF1 P340P G122711341A 1.29 (1.19–1.43) 1.49E-07 3.89E-06
rs7021880 TRAF1 intronic C122713711G 1.33(1.21–1.46) 5.41E-09 2.27E-07
rs7021049 TRAF1 intronic G122723803T 1.32 (1.20–1.43) 4.09E-08 1.22E-06
rs2900180 T122746203C 1.27 (1.18–1.41) 3.32E-07 7.62E-06
rs2269066 C5 intronic T122776839C 1.29 (1.14–1.53) 1.68E-04 0.001
rs2269067 C5 intronic C122776861G 1.27 (1.17–1.46) 1.71E-05 1.04E-04
rs2159776 C5 intronic C122795981T 1.11 (0.99–1.19) 0.190 0.135
rs7040033 C5 intronic A122798865G 0.86 (0.80–0.96) 0.018 0.060
rs17611 C5 I802V A122809021G 0.84 (0.79–0.94) 0.006 0.040
rs10985126 C5 G385G C122823755T 1.20 (1.11–1.39) 8.69E-04 0.001
rs2416811 C5 intronic T122829455C 0.85 (0.79–0.95) 0.008 0.023
rs1323472 C122866156G 1.23 (1.12–1.34) 1.57E-04 7.06E-04
rs9657673 CEP110 intronic T122900196C 0.86 (0.81–0.96) 0.019 0.052
rs10081760 CEP110 intronic A122924127G 1.15 (1.03–1.25) 0.049 0.066
rs12683062 CEP110 intronic T122946625G 1.12 (1.00–1.33) 0.209 0.029
rs3747843 CEP110 intronic A122954127G 1.13 (1.01–1.21) 0.108 0.304
rs3736855 CEP110 V1398V A122956841T 0.87 (0.82–0.98) 0.048 0.191
rs10760152 RAB14 intronic A122987806C 1.15 (1.05–1.27) 0.028 0.024
rs942152 RAB14 intronic C122991506T 1.18 (1.11–1.32) 2.53E-04 0.002
rs9408928 RAB14 intronic C122991738T 1.11 (0.93–1.38) 0.364 0.378
rs9409230 T123007581A 1.14 (0.93–1.40) 0.499 0.217
rs7030849 C123009655T 1.18 (1.08–1.29) 0.003 0.014
rs10985196 GSN intronic A123072865C 1.25 (1.18–1.46) 6.33E-07 4.12E-06
rs306781 GSN intronic C123082765T 0.68 (0.59–1.16) 0.119 0.284
rs7046030 GSN intronic C123087058T 1.26 (1.18–1.47) 2.05E-06 1.99E-05
rs12683459 GSN intronic A123088119G 1.25 (1.18–1.47) 1.36E-06 9.79E-06
rs4837839 GSN intronic T123111948C 0.85 (0.82–0.97) 0.021 0.076
rs306783 GSN intronic T123112418C 1.11 (1.00–1.19) 0.198 0.405
rs306784 GSN intronic T123112473G 1.15 (1.03–1.24) 0.049 0.131
rs10818527 GSN intronic A123115075G 1.21 (1.08–1.31) 0.001 0.004
rs12683989 GSN intronic T123125867C 1.17 (1.05–1.50) 0.016 0.010
aPositions according to genomic contig NT_008470.18 (Entrez Nucleotide). The minor allele is listed first, followed by the position in National Center for Biotechnology
Information Genome Build 36.2 and then the major allele.
bCalculated for the minor allele using a Mantel-Haenszel common OR.
cCalculated using Fisher’s combined test.
doi:10.1371/journal.pgen.1000107.t002
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significant results for both single markers and haplotypes in this
region. Second, the association signal at this region shows a higher
degree of consistency across the three studies. Indeed, Sample Set
3 haplotypes in the RAB14-GSN region show very little deviation
from the null hypothesis (Figure 3). Finally, as discussed above, a
subset of SNPs in the RAB14-GSN region (e.g. rs10985196,
rs7046030, rs12683459) displayed substantial differences in
control allele frequencies between the two North American groups
(Table S1) drawing into question the validity of the association
results for these SNPs.
Haplotype Analyses of LD Block 1 Variants
While both the single marker and sliding window haplotype
analyses pointed to LD Block 1 as harboring RA-associated SNPs,
these analyses did not identify a single SNP that was clearly the
most significant across all three studies. The TRAF1 intronic SNP,
rs7021880, was the most significant SNP in Sample Sets 1 (trend
P=3.12E-04) and 2 (trend P=5.09E-07) and in the combined
analysis (trend Pcomb = 5.41E-09); however, this SNP was not
significant in the Dutch sample set (trend P= 0.102) where the
Group 2 SNPs, rs4836834 and rs7021049, were the most
significant (trend P= 0.004 and 0.006, respectively) (Tables S1
and S2). Interestingly, these Group 2 SNPs ranked second in
significance in Sample Set 1 and in the combined analysis while in
Sample Set 2 they ranked third behind rs7021880 and the Group
1 SNPs.
Given these results, we analyzed the haplotype structure of LD
Block 1 using a subset of the nine SNPs from this region genotyped
in all three studies. Taking into account the LD structure we
picked rs2239657, the P340P TRAF1 synonymous polymorphism
to represent the six Group 1 SNPs; rs7021049, a TRAF1 intronic
SNP to represent the two Group 2 SNPs; and rs7021880 for these
analyses. Haplotype frequencies for these three SNPs were
estimated using the Haplo.Stats package [39] revealing the same
four common haplotypes in each study (Table 3). Two of these
haplotypes, AGT and GCG were strongly associated with disease
(Pcomb = 3.08E-08 and 8.00E-09, respectively), with the former
being protective – decreasing in frequency from ,60.9% in North
American controls to 53.8% in North American cases and 56.7%
in Dutch controls to 51.2% in Dutch cases (ORcommon = 0.76,
95% CI 0.70–0.83); and the latter susceptible – 27.0% in North
American controls increasing to 34.7% in North American cases
and 33.2% in Dutch controls increasing to 36.0% in Dutch cases
(ORcommon = 1.32, 95% CI 1.21–1.45). These haplotype Pcomb-
values were not significantly different from those calculated for the
individual SNPs (Table 2) suggesting there is no strong evidence
for synergistic cis-acting effects between these variants.
Dosage Effects
To explore the effect of the number of copies of each haplotype
at these three sites (rs2239657, rs7021880 and rs7021049) along
with any dominant/recessive effects between haplotypes, we
estimated diplotypes using the pseudo-Gibbs sampling algorithm
from the program SNPAnalyzer [40]. Analyzing the diplotypes
individually, two diplotype combinations achieved statistical
significance (P,0.01) when compared to all other diplotypes
(Table 4). The AGT/AGT diplotype was strongly associated with
protection against RA (ORCommon = 0.68, 95%CI 0.59–0.78;
PComb = 5.35E-07), whereas the less frequent GCG/GCG diplo-
type was associated with predisposition (ORCommon = 1.42, 95%CI
1.16–1.75; PComb = 0.005).
Assuming a disease prevalence of 1%, we calculated the relative
risk of RA in those individuals carrying 2 copies of the protective
AGT haplotype compared to those without the AGT haplotype
Figure 3. A five-SNP sliding window haplotype analysis of the 9q33.2 region. Each sample set is shown separately with the combined
analysis in bolded black. The approximate location of the PHF19, TRAF1, RAB14 and GSN genes are listed above.
doi:10.1371/journal.pgen.1000107.g003
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(RR2 copies AGT=0.77). This homozygous relative risk was substan-
ftially reduced from the relative risk calculated for individuals
carrying only one copy of the AGT haplotype (RR1 copy AGT
=1.06.). Similarly, we estimated the relative risks for the suscep-
tible GCG haplotype (RR2 copies GCG=1.38; RR1 copy GCG=
1.15).
Genetic Background-Conditioned Results
We used a collection of 749 SNPs informative for European
substructure to stratify both the cases and controls in Sample Set 2
[41]. By partitioning cases and controls into similar genetic
background groups (‘‘Northern European’’ or ‘‘Other’’), our aim
was to interrogate the data for strata-specific effects – that is,
whether or not association signals were specific to one of these
genetic background groups – and avoid potential confounding by
population stratification. Although two SNPs demonstrated
moderately higher significance levels following stratification –
rs16910233 in C5 (PNorth = 0.019 compared to PUnstrat = 0.147)
and rs12685539 in CEP110 (POther = 0.038 compared to PUnstrat =
0.115), a Breslow-Day test of effect heterogeneity comparing
ORNorth and OROther was not significant. Furthermore, a
positional plot of Mantel-Haenszel P-values, testing for association
given the genetic background stratification, was very similar to the
unadjusted plot (Figure S1) suggesting that stratification of the case
and control samples by SNPs informative for European substruc-
ture did not change the association patterns in Sample Set 2.
Rheumatoid Factor (RF)
Rheumatoid factor, a circulating antibody to immunoglobulin
G, is a key serum analyte used in diagnosis of RA as well as an aid
for the prognosis of RA-severity [2]. As the R620W missense
polymorphism in PTPN22 appears to have stronger susceptibility
effects for RF-positive disease [9–11] and since RF is clinically
important, we investigated the role of RF status on the chr 9q33.2
association patterns for the three LD Block 1 SNPs, rs2239657,
rs7021880 and rs7021049, testing for both strata-specific effects as
well effect size differences between RF-positive and RF-negative
disease.
To explore the effect isolated to RF-positive patients compared to
controls, we performed a strata-specific analysis for all sample sets
using a genotypic test. The resulting combined P-values for the RF-
positive stratum were highly significant (Prs2239657 = 4.02E-05,
Prs7021880= 7.10E-06, Prs7021049= 5.68E-06; Table 5), which were
slightly less significant when compared to the overall genotypic
combined P-values (Table 2). A similar analysis of RF-negative
disease in Sample Sets 2 and 3 yielded genotypic combined P-values
of Prs2239657= 0.038, Prs7021880= 0.013 and Prs7021049= 0.082. Allelic
odds ratios and 95% confidence intervals were also calculated for
each individual sample set and the results did not demonstrate a clear
pattern of strata-specific effects within a stratum or differential effects
between the two strata (Table 5). A Breslow-Day test was performed
on Sample Set 2 (individually matched cases and controls) to
formalize the test of homogeneity of odds ratios, showing that none
of the three SNPs exhibited significant differential effects (Table 5).
Similarly, results for the analogous Monte Carlo-based test
performed in Sample Set 3 (where cases and controls were not
individually matched) also did not reveal significant heterogeneity
between RF-positive and RF-negative effects.
Logistic Regression
To further dissect association signals from LD patterns, build
predictive models and explore the relative effects of each SNP
within the models constructed we used logistic regression. To
accomplish this we first minimized the number of SNPs for these
analyses by calculating pairwise r2 values for the 43 SNPs
genotyped in all three sample sets and divided the SNPs into
distinct groups based on their LD structure. SNPs with pairwise r2
values .0.90 were grouped together resulting in 27 distinct groups
(Table 6) and then the single most significant SNP from each
group (Pcomb from Table 2) was chosen for the logistic regression
analyses.
In the univariate analysis, the TRAF1 intronic SNP rs7021049,
which marks the Group 2 SNPs in LD Block 1, was the most
significant SNP (P= 1.24E-06), followed by rs7021880 (1.39E-06)
and then the Group 1 SNP, rs2239657 (P= 2.52E-06) (Table 6). In
addition, 11 other SNPs were significant (P,0.01). To assess
whether other observed associations in the region were primarily a
result of LD with the most significant SNP, we performed pairwise
logistic regression on all 27 SNPs adjusting for rs7021049. One
SNP retained modest statistical significance (P,0.01): rs10985196
(Group 21), a GSN intronic SNP (P= 0.001). To test whether the
combination of the rs7021049 and rs10985196 variants fully
accounted for the association with RA, we repeated the logistic
regression adjusting for both; none of the remaining groups of
SNPs were significantly associated with RA. It should be noted,
however, that analyses of each individual sample set suggested the
evidence for association with rs10985196 (Group 21) was primarily
driven by the data from sample set 2 (data not presented).
To explore more complex models, we used both forwards and
backwards stepwise logistic regression procedures separately on
the same 27 SNPs in each individual sample set as well as in a
combined analysis of all three sample sets. The final models
generated from the stepwise procedures, however, were inconsis-
tent across the sample sets (Table S2). In fact, seven distinct models
were produced; the only instance where the same model was
produced was for both the forwards and backwards models of
Sample Set 2. Not surprisingly, the forward model for the
combined samples, which included two SNPs, rs7021049 (the
Group 2 TRAF1 intronic SNP) and rs10985196 (the GSN intronic
SNP), was consistent with the results of the pairwise logistic
regression analysis presented above.
Multi-Locus RA Risk Calculations
Given that we have begun to witness the application of
associated genetic variants to disease prognosis [42,43] and thus
far we have convincing evidence for three RA-predisposing loci in
our studies (HLA-DRB1, PTPN22 and the TRAF1 region), we
estimated the risk of RA given genotypes at these three loci under
three different possible unconditional RA risk assumptions (i.e. RA
disease prevalence values) using Bayes’ theorem. In total, there
were 18 multi-locus genotype combinations and RA risk was
calculated for each combination using data from Sample Set 1 as
described in the Materials and Methods. Assuming a 1% RA
prevalence, similar to that observed in the white North American
general population, the results indicate that individuals with the
protective genotype at all three loci (0SE for HLA-DRB1, CC
genotype for PTPN22 and the AGT/AGT TRAF1 diplotype) have
a substantially reduced predicted risk of RA (0.29% vs. 1%),
whereas those individuals in the highest-risk category (HLA-2SE,
TT or TC genotype at PTPN22, and the GCG/GCG TRAF1
diplotype), have an estimated RA risk of 13.06% – representing
more than a 45-fold increase in risk (Table S3). These data are
presented as a 3-D plot in Figure 4 where the lowest risk value has
been reset to 1 and the other values normalized accordingly.
Approximately 19% of the general population will find themselves
in the low-risk multi-locus genotype category and only 0.06% in
the high risk group. In contrast, when the disease prevalence is
increased to 30%, as might be observed in high-risk groups such as
TRAF1 Variants on Chr 9q33.2 and RA
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an early arthritis clinic, the range of risk drops to 7.88-fold, with
the posterior probability of RA calculated to be 11% for the
lowest-risk genotype combination and increasing to 86.4% in the
highest risk category (Table S3).
Discussion
We undertook a large-scale, multi-tiered association study of RA
using a panel of putative functional SNPs that have been
successfully applied to case-control studies of other disease
phenotypes [32,44–47]. The initial step of this large-scale RA
association study, individual genotyping of 87 prioritized SNPs to
evaluate DNA quality prior to constructing DNA pools for our
scan, led to the identification of the PTPN22 R620W SNP [9].
This SNP has been both widely replicated and associated with
multiple autoimmune diseases [11].
The present study focuses on variants in the chr 9q33.2 region
that were also convincingly correlated with RA status. In
particular, three groups of SNPs, represented by rs2239657
(Group 1), rs7021049 (Group 2) and rs7021880 were highly
significant and showed a localized effect to a 70 kb region
extending from rs10985070, in intron 3 of PHF19, across TRAF1
to rs2900180 in the TRAF1-C5 intergenic region, but excluding
the C5 coding region (LD Block 1 in Figure 1). Examination of the
CEU HapMap data identified 16 additional SNPs that were highly
correlated (r2.0.95) with either the Group 1 or Group 2 SNPs
genotyped in this study (Figure 2C) and all 16 fall within this 70 kb
region (no such SNPs were found for rs7021880). Across sample
sets, the evidence for association at these sites was stronger,
maintaining statistical significance after correction for multiple
testing, and more consistent than sites in neighboring regions.
Additional analyses further buttressed the statistical support for
these conclusions: (i) a haplotype sliding window analysis of all
SNPs genotyped in the chr 9q33.2 region demonstrated strong
statistical evidence for the TRAF1-region harboring RA risk
variants (Pcomb= 4.15E-08) and (ii) haplotype analysis of SNPs
within the 70 kb LD Block 1, identified a common protective
haplotype (Pcomb = 3.08E-08) and a less frequent risk haplotype
Table 6. Pairwise logistic regression analysis of 27 chr 9q33.2 SNPs.
Groupa Marker
r2 with
rs7021049b Pc
P adjusted for
rs7021049
P adjusted for
rs7021049 &
rs10985196
3 rs10760112 0.157 0.357 0.285 0.770
4 rs10760117 0.329 0.011 0.760 0.579
5 rs10739575 0.086 0.055 0.580 0.893
6 rs933003 0.011 0.757 0.420 0.448
7 rs1837, rs7026635 0.151 0.002 0.169 0.126
8 rs1056567 0.243 5.22E-04 0.200 0.208
1 rs2239657, rs1953126, rs1609810, rs881375, rs6478486, rs2900180 0.685 2.52E-06 0.217 0.254
9 rs7021880 0.607 1.39E-06 0.104 0.072
2 rs7021049, rs4836834 1 1.24E-06 – –
10 rs2269066 0.114 0.002 0.115 0.094
11 rs2269067 0.261 7.64E-06 0.023 0.175
12 rs2159776 0.143 0.291 0.367 0.598
13 rs17611, rs7040033, rs2416811, rs9657673, rs3736855 0.328 0.011 0.716 0.450
14 rs10985126 0.206 1.86E-04 0.103 0.992
15 rs1323472, rs7030849 0.585 1.99E-04 0.935 0.415
16 rs12683062 0.113 0.042 0.696 0.327
17 rs3747843 0.337 0.112 0.123 0.059
18 rs10760152, rs10081760 0.297 0.007 0.933 0.790
19 rs942152 0.434 2.92E-05 0.161 0.919
20 rs9408928, rs9409230 0.063 0.270 0.955 0.307
21 rs10985196, rs7046030, rs12683459 0.089 6.17E-06 0.001 –
22 rs306781 0.015 0.905 0.661 0.147
23 rs4837839 0.079 0.171 0.988 0.667
24 rs306783 0 0.192 0.210 0.987
25 rs306784 0.009 0.054 0.144 0.876
26 rs10818527 0.02 0.007 0.044 0.368
27 rs12683989 0.019 0.009 0.054 0.573
aSNPs were grouped together if their pairwise r2 values were .0.90. The first SNP in each group was used for the analyses. With the exception of Groups 1 and 2, they
are listed in order of appearance on the chromosome (for groups of SNPs we used the position of the first SNP). To avoid confusion, we retained the identity of the
Group 1 and 2 SNPs assigned in Figure 2.
bPairwise LD between rs7021049 and each of the 27 other SNPs as measured by r2 in the cases and controls of the combined analysis of all three sample sets.
cUnivariate analysis using logistic regression.
doi:10.1371/journal.pgen.1000107.t006
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(Pcomb = 8.00E-09). The three representative SNPs (rs2239657,
rs7021049 and rs7021880) were strongly associated with RF-
positive disease and trended towards association in RF-negative
disease although the small number of RF-negative patients in our
study precludes drawing statistically meaningful conclusions about
the role of these SNPs in this patient population.
To tease apart association signals from LD patterns, we used
logistic regression. The pairwise analyses of the combined datasets
suggest there may be two independent statistical signals of
association to RA at chr 9q33.2 – one in the TRAF1 region
represented by rs7021049 and one in the GSN region represented
by rs10985196 (Table 6); however, analyses of the individual
sample sets showed rs10985196 was independently associated with
disease risk in Sample Set 2 only while rs7021049 showed
consistent association across all three sample sets (data not
presented). Consequently, additional samples are needed to
determine whether the GSN region truly contains RA-predisposing
effects.
To explore more complex models and assess whether SNPs
outside of LD Block 1 were incorporated into these models, we
used both forwards and backwards stepwise logistic regression.
The sets of SNPs included in the models chosen by the stepwise
procedures were inconsistent indicating that the observed
association in the region is not clearly explained by a single SNP
or set of SNPs included in the tested models.
Independently, Plenge and colleagues [34], using a whole
genome association (WGA) study, and Kurreeman and coworkers
[35], using a candidate gene approach, have also shown this chr
9q33.2 region is associated with RA risk in whites of European
descent. Although a partially overlapping subset of samples was
used in all three studies (see Table 1 footnotes), each study
employed unique experimental designs, analyses and presented
different facets of the 9q33.2-RA association. Plenge and
colleagues [34] identified rs3761847, a TRAF1/C5 intergenic
SNP, as one of two non-MHC SNPs reaching genome-wide
significance in their WGA study; not surprisingly, the other
significant non-MHC SNP was in PTPN22. Their follow-up fine
mapping of the chr 9q33.2 region with nine haplotype tag SNPs in
four RA sample sets (2519 cases / 3627 controls) localized the
region of interest to 100 kb extending from PHF19 into C5.
rs3761847, which is a Group 2 SNP in LD Block 1, remained the
most significant SNP in their combined analysis (P = 4.00E-14)
followed by rs2900180 (P= 8.00E-14), a member of the Group 1
SNPs in LD Block 1.
Taking a candidate gene approach, Kurreeman and colleagues
[35] studied 40 SNPs in a 300 kb region surrounding C5 (from the
39 UTR of PHF19 to intron 25 of CEP110) in a staged-approach in
four sample sets (2,719 cases / 1999 controls) and concluded that
rs10818488, another TRAF1-C5 intergenic SNP and member of
the LD Block 1 Group 2 SNPs, was the SNP most significantly
associated with a diagnosis of RA in their study. Association of a
Group 1 SNP, rs2416806, was moderately significant in a
combined analysis of three of their sample sets (P = 0.015). Neither
the Plenge et al. nor Kurreeman et al. study included rs7021880.
Our analyses, which included more SNPs and incorporated
HapMap information for all SNPs highly correlated with SNPs
genotyped in our study, permitted a comprehensive analysis of the
genetic architecture of 9q33.2 region, allowing us to localize the
RA-susceptibility effects to a 70 kb region (LD Block 1) that
includes a portion of PHF19, all of TRAF1 and the majority of the
TRAF1-C5 intergenic region, but excludes the C5 coding region,
narrowing the true region of interest. Our data, however, did not
Figure 4. Relative risk plotted as a function of the genetic load of three validated RA risk variants in HLA-DRB1, PTPN22 and TRAF1.
Individuals are classified according to the number of copies of the HLA-DRB1 shared epitope (0, 1 and 2) (SE-positive HLA-DRB1 alleles found in this
sample set were: 0101, 0102, 0401, 0404, 0405, 0408 and 1001), carriage of the W620 PTPN22 missense SNP (TT + CT vs CC) and diplotypes at the
TRAF1 SNPs, rs2239657, rs7021880 and rs7021049. The frequency of each combination of markers in cases and controls is highlighted in white (case/
control).
doi:10.1371/journal.pgen.1000107.g004
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allow us to identify a single SNP or group of highly correlated
SNPs (r2.0.95) in this 70 kb region that unambiguously explained
the association signal in all three independent sample sets. Other
sample sets with different patterns of LD or functional studies will
be required to resolve this issue.
Interestingly, Potter and colleagues [48], who studied 23
haplotype-tagging SNPs from the 6 TRAF genes, including three
from TRAF1, in a UK case-control study (351 RA cases / 368
controls) failed to see association with both a Group1 (rs1468671)
and a Group2 (rs4836834) SNP. Using an overlapping sample set
to the Potter et al study, the recent Welcome Trust Case Control
Consortium genome-wide association study of RA (1860 cases /
2930 controls) [25] also failed to identify RA-risk variants in this
region. However, a more recent follow-up study from the same
group of an independent RA sample set from the UK (3418 cases
/ 3337 controls) confirmed association with four LD Block 1
Group 2 SNPs although the effect size was less (meta analysis OR
1.08, 95%CI 1.03–1.14) [49].
The original RA-associated, 9q33.2 SNP identified in our
genome-wide scan, rs1953126, is located within LD Block 1, 1 kb
upstream of the 59 end of PHF19, the human homologue of the
Drosophila polycomblike protein, PCL, gene. In Drosophila, the
protein encoded by this gene is part of the 1MDa extra sex combs
and enhancer of zeste [ESC-E(Z)] complex which is thought to
mediate transcriptional repression by modulating the chromatin
environment of many developmental regulatory genes such as
homeobox genes. While the exact function of this gene in humans
remains unknown, it encodes two nuclear proteins that appear to
be upregulated in multiple cancers and preliminary evidence
suggests that deregulation of these genes may play a role in tumor
progression [50].
TRAF1 encodes a protein that is a member of the TNF receptor
(TNFR) associated factor (TRAF) protein family that associates
with, and mediates signal transduction from various receptors
including a subset of the TNFR superfamily. There are six
members of this family of adaptor proteins; however, TRAF1 is
unique in that while it contains the hallmark carboxyl-terminal
TRAF domain, it has a single zinc finger in the amino-terminal
part and the N-terminal RING finger domain, required for NF-kB
activation, is missing. TRAF1 appears to have both anti-apoptotic
and anti-proliferative effects [51,52]. In addition, this protein has
been found to be elevated in malignancies of the B cell lineage
[53–58]. This observation is interesting given the risk of
lymphoma, particularly diffuse large B cell lymphomas, appears
to be increased in the subset of RA patients with very severe
disease, independent of treatment [59,60]. Although the precise
mechanism of TRAF1 action in various signaling pathways has
not been fully elucidated, it is clear that this molecule plays an
important role in immune cell homeostasis making it an excellent
candidate gene for RA. In fact, in vitro work suggests that TNFa-
mediated synovial hyperplasia, a major pathophysiologic feature of
RA, may be correlated with upregulation of TRAF molecules,
particularly TRAF1 [61]. Given that TNF blockade has proved a
highly effective therapy for RA [62,63] and response to TNF-
antagonists among RA patients is known to vary, investigation of
whether the TRAF1 variants identified in this study play a role in
this differential response may be a fruitful pharmacogenetic
avenue to pursue.
C5 is also an excellent RA candidate gene and although our
analyses allowed us to exclude the C5 coding region, SNPs in LD
Block 1 could differentially regulate the expression of this gene. C5
encodes a zymogen that is involved in all three pathways of
complement activation. Traditionally, the complement system has
been viewed as a central part of the innate immune system in host
defenses against invading pathogens and in clearance of potentially
damaging cell debris; however, complement activation has also
recently been implicated in the pathogenesis of many inflamma-
tory and immunological diseases. Proteolytic cleavage of C5 results
in C5a, one the most potent inflammatory peptides, and C5b, a
component of the membrane attack complex (MAC) that can
cause lysis of cells and bacteria. Genetic studies in various mouse
models of RA, including collagen-induced arthritis (CIA) and the
K/BXN T cell receptor transgenic mouse model of inflammatory
arthritis have provided evidence that C5 or a variant in strong LD,
plays a role in disease [64–66]. More striking is the observation
that anti-C5 monoclonal antibody therapy can prevent and
ameliorate disease in both mouse models [67,68].
In summary, we have independently identified a region on chr
9q33.2 as a risk locus for RA. Although the evidence from the
SNPs genotyped in our sample sets most strongly points towards
TRAF1 variants as being the most highly consistent with a disease
model, the high LD that extends from the 59 end of PHF19
through TRAF1 and into the TRAF1-C5 intergenic region
precludes conclusively determining causative genes or functional
motifs through genetic means in these samples. Mapping studies in
additional sample sets with a different LD architecture and/or
functional studies will be required to resolve the molecular
relevance of these findings.
Aside from the possibility of developing targeted therapies with
knowledge of predisposing variants underlying the onset of RA,
the identification of RA susceptibility alleles may encourage earlier
monitoring and provide an intervention avenue in advance of
significant joint erosion. Our initial analysis of the three known
genetic risk factors, HLA-SE, PTPN22 and the chr 9q33.2 variants
described here, suggests a .45 fold difference in RA risk
depending on an individual’s genotype at these three loci. As
additional markers are identified, the ability to accurately predict
individuals at increased risk for developing RA, particularly within
families with a history of RA, may prove useful. Finally, differential
risk variants may prove to be drug response markers.
Materials and Methods
Subjects and Samples
All RA cases included in this study were white and met the 1987
American College of Rheumatology diagnostic criteria for RA
[69]; informed written consent was obtained from every subject.
Sample Set 1, which consisted of 475 RA cases and 475
individually-matched controls, was collected by Genomics Col-
laborative, Inc. All case samples were white North Americans of
European descent who where rheumatoid factor (RF) positive.
Control samples were healthy white individuals with no medical
history of RA, also of European descent. A single control was
matched to each case on the basis of sex, age (65 years), and self-
reported ethnic background. The 661 cases in Sample Set 2 were
acquired from the North American Rheumatoid Arthritis
Consortium (NARAC) (http://www.naracdata.org/) and consist-
ed of members from 661 white North American multiplex families
[33,70,71]. Both RF-positive and RF-negative patients were
included in this sample set. Controls for Sample Set 2 were
selected from 20,000 healthy individuals enrolled in the New York
Cancer Project [72], a population-based prospective study of the
genetic and environmental factors that cause disease (http://www.
amdec.org/). Two control individuals were matched to a single,
randomly chosen affected sibling from each NARAC family on the
basis of sex, age (decade of birth), and self-reported ethnic
background. Sample Set 3 was composed of 596 white RA patients
from the Leiden University Medical Centre and 705 white
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controls from the same geographic region in The Netherlands
[73–75]. Both RF-positive and RF-negative patients were included
in this sample set. Table 1 displays the clinical characteristics of all
three sample sets and a detailed description of samples that overlap
with published studies of this region [34,35].
Functional Genome-Wide Scan
Our functional genome-wide scan included 25,966 gene-centric
SNPs curated from dbSNP, the Applera Genome Initiative [44,76]
and the literature. SNPs were included if they appeared in more
than one database and had a minor-allele frequency .1%.
Approximately seventy percent of the SNPs were annotated as
missense polymorphisms. The majority of the remaining SNPs
were either located within putative transcription-factor site motifs
or within acceptor/donor splice site regions or were nonsense
polymorphisms.
Genotyping
Allele-specific, real-time quantitative PCR [77] was used to
amplify 3 ng of pooled DNAs and infer SNP allele frequencies as
previously detailed [44]. Individual genotyping on SNPs was
performed on 0.3 ng of DNA using a similar protocol. Blinded to
case-control status, custom-made in-house software was used to
call genotypes, followed by hand-curation. Individual genotyping
accuracy has been estimated to be.99.8% by comparison with an
independent method. HLA-DRB1 genotyping was performed using
sequence-specific oligonucleotide probes as previously described
[9]. Shared epitope (SE) status [78] was determined from the
probe hybridization patterns. For this study, DRB1 alleles positive
for the SE include: 0101, 0102, 0401, 0404, 0405, 0408 and 1001.
Fine-Scale Mapping SNP Selection
To identify SNPs for inclusion in our fine-scale mapping effort
of the 9q33.2 region, we first postulated two different disease
models: 1) a model where the originally identified SNP is in linkage
disequilibrium with one or more causative SNPs and 2) a model of
allelic heterogeneity where several alleles at the locus indepen-
dently predispose individuals to RA. To address both of these
models, we first defined the region to be interrogated by
calculating pairwise linkage disequilibrium (r2) values between
the originally identified SNP 59 of PHF19, rs1953126, and all
HapMap-genotyped SNPs (http://www.hapmap.org/) within 500
kb flanking either side for the CEPH samples (Utah residents with
ancestry from northern and western Europe, or CEU individuals)
[36]. With this information, we defined a broad region spanning
668 kb from MEGF9, 177 kb upstream of rs1953126 , to STOM,
491 kb downstream of rs1953126, for follow-up genotyping. SNPs
within this region were partitioned into those in moderate to high
LD (r2.0.20) with rs1953126 to address the first model, and those
in low LD (r2,0.20) with rs1953126 to address the second model.
The power-based SNP selection program Redigo [79] was then
used on the low LD set of SNPs to identify a reduced number of
SNPs (tagging SNP set) that retained high power to detect
association. Those SNPs in moderate to high LD with the original
SNP were reduced by selecting a subset of representative SNPs of
any groups exhibiting extremely high inter-group LD (r2.0.98).
Further, any putative functional SNPs were automatically included
in the fine-scale mapping effort if we were able to construct high-
quality genotyping assays for them. The resulting set of 137 SNPs
was genotyped in Sample Set 1 and the data analyzed. Additional
removal of fine-scale mapping SNPs was performed for evaluation
in subsequent sample sets on the basis of association results and
refined LD patterns: a subset of 72 SNPs were selected for
genotyping in Sample Set 2 and 42 SNPs were genotyped in
Sample Set 3.
Statistical Analyses
The Cochran-Armitage trend test [80] was used to calculate P-
values for individual SNPs. A William’s-corrected G-test [37] was
used to calculate P-values for genotypic association. P-values were
corrected for multiple testing using the method of Dunn-Sidak
[37]. Odds ratios and confidence intervals were calculated
according to standard procedures. Hardy-Weinberg equilibrium
testing was accomplished through the exact test of Weir [81]. P-
values were combined across sample sets using the Fisher’s
combined P-value, or omnibus procedure [82]. Likewise, Mantel-
Haenszel common odds ratios [83] were calculated to combine
data across sample sets. To avoid the small-count limitations of
asymptotic-derived confidence intervals, a Monte Carlo simulation
was written in XLISP-STAT to calculate 95% confidence intervals
on the Mantel-Haenszel common odds ratios. We typically
performed 20,000 iterations of the Monte Carlo for these
confidence intervals. The standard measure of pairwise linkage
disequilibrium (the r2 statistic from estimated 2-site haplotypes)
was used to characterize the genetic architecture of the region.
The program LDMAX with an EM algorithm was used to
perform the r2 calculations [84].
Genetic Analyses
Haplotype Analysis. Haplotypes were estimated from
unphased genotype data and evaluated for association with RA
through the Haplo.Stats software package [39]. A sliding window
of haplotype association was calculated using a window size of 5
SNPs. Global P-values (calculated across all haplotypes within a
window) and haplotype-specific ORs and P-values were
calculated. Additional haplotype analyses were performed using
a combination of the Pseudo-Gibbs sampling algorithm in the
program SNPAnalyzer (http://snp.istech.info/snp/SNPAnalyzer.
html) [40] and the Haplo.Stats package.
Genetic Background-Conditioned Analysis. A panel of
749 SNPs previously selected to be informative for classifying
individuals of European descent into northern and southern
geographical groups was applied to case and control samples from
the second sample set as described previously [41]. Applying this
method, we placed 367 cases and 525 controls from Sample Set 2
into a northern European ancestry cluster. Each case or control
individual had a greater than 0.95 probability of belonging to the
northern European cluster. The remaining cases and controls from
this study were binned into an ‘‘Other’’ category. A Breslow-Day
analysis [85] was applied to the stratified data to test for
heterogeneity in ORs between the two groups for the 9q33.2-
linked SNPs studied here. To test for association conditioned on
these stratified data, we also calculated a Mantel-Haenszel P-value
[83].
Subphenotype Analysis: Rheumatoid Factor. Rheuma-
toid Factor (RF) levels were measured in cases as previously
described [86,87]. To test for heterogeneity of effect between RF-
positive and RF-negative patients we used two different methods.
In sample set 2, where case-control matching was part of the study
design, we used the Breslow-Day [85] test. Since individual
matching was not incorporated into Sample Set 3, we used a
Monte Carlo simulation to compare the effect size for RF-positive
patients versus all controls to the effect size for RF-negative
patients versus all controls. Similar to other tests of homogeneity of
odds ratios, we constructed a test statistic measuring the departure
between normalized odds ratios comparing two groups (see
equation S1 in Text S1) and ran a Monte Carlo simulation to
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account for correlated odds ratios in the null distribution. Monte
Carlo P-values were calculated in the traditional manner.
Logistic Regression. Logistic regression models were
performed to assess the relative importance of 27 SNPs chosen
as distinct representatives of groups of SNPs with pairwise r2
values ..90. First, a logistic regression model for each unique pair
of SNPs was performed. These pairwise models assumed a
multiplicative effect on the risk of RA for each additional copy of
an allele. P-values and odds ratios for the effect of each SNP, when
controlling for each alternative SNP, were examined visually to
determine if any SNP showed obvious patterns (attenuating the
risk of each alternate SNP and retaining risk when adjusted for
each alternate SNP). These types of patterns might be expected
under a disease model of a single functional SNP. For models in
which both SNPs remained strongly associated (P,.01), additional
models were performed to determine if adding a third SNP
significantly improved the model. To examine multi-SNP
relationships in a more automated fashion in a manner similar
to that suggested by Cordell and Clayton [88], both a forward as
well as a backward stepwise logistic regression procedure was
performed on each sample set individually as well as on the
combined sample sets. The stepwise models were performed
coding the genotypes with indicator variables and with a
significance level of 0.05 for the two degree of freedom score
test (for entry) or Wald test (for exit) on the effect of the SNP used
as a threshold for entry or exit from the model. Models applied to
the combined sample sets also forced sample set as a covariate in
the model. The final model from each procedure was also applied
to the other sample sets to assess consistency of the models across
sample sets. The P-value from the likelihood ratio test of the global
null hypothesis for each model is reported for single studies while
for the combined study we report a P-value from a likelihood ratio
test comparing the model containing the SNPs and the variable
representing sample set to a model containing only the same
sample set variable. All logistic regression models were performed
using SAS version 9.
Multi-Locus RA Risk Calculations. Risk for RA given
every possible 3-locus genotype combination at the HLA-DRB1
shared epitope, the R620W SNP in PTPN22, and 3-SNP TRAF1
diplotypes was calculated for sample set 1 using Bayes’ theorem
(see equations S2 and S3 in Text S1) assuming conditional
independence between loci (the commonly-used Naive Bayes
model for predictive modeling) and a range of RA prevalence
values (1%, 10% and 30%). Theoretical calculations (not shown)
demonstrate that unless both sample sizes and epistatic effects are
very large, probability estimates of the jointly-occurring genotypes
have lower error rates assuming conditional independence
between loci. Therefore, fully-factorizing the probability of
multi-locus genotypes (using the conditional independence
assumption) is warranted under a broad range of the parameter
space. By estimating the posterior probability of RA for every
possible multi-locus genotype combination, accurate individual-
based prognosis is possible. Confidence intervals on the relative
risk estimates were obtained through simulation. It is important to
note that due to the selection of loci for inclusion in the model,
some overfitting may be present.
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Figure S1 Genetic background-conditioned analysis. Allelic
association for individual SNPs genotyped in Sample Set 2 (in
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